Norway Archives

norway cytovation cancer immuno oncology

News and Trends 26 Jan 2022

Norwegian Biotech Put on the Map with €18M Oncology Round

The immuno-oncology startup Cytovation has raised €17.7M (NOK 180M) in one of Norway’s biggest Series A rounds in life sciences. Historically, Norway’s biotech scene has not seen the kind of venture capital funding characteristic of health and biotech in the UK and US. However, Norwegian biotech is growing and has seen more successes than many […]

January 26, 2022 - 3 minutesmins - By Dan Samorodnitsky

Interview 9 Sep 2020

Biotech Investment in Norway: An Alternative Approach

Norway has not typically been an attractive region for biotech investors, so when Masha Strømme set up her own investment firm in 2008, she had to take a slightly different approach to investment. Masha Strømme and her husband, Dag Strømme, run a family office together called Paacs Invest in the Oslo area, which funds and […]

September 9, 2020 - 6 minutesmins - By Helen Albert

Startup Scout 1 Feb 2019

This Biotech Links the Gut Microbiome to Diseases Using Norwegian Poo

In Norway’s capital city of Oslo, the biotech Bio-Me can rapidly screen for specific gut bacteria, gathering data from thousands of Norwegian stool samples to link the gut microbiome to diseases. Mission: To rapidly screen thousands of stool samples from a Norwegian population study and link the gut microbiome with disease. Client companies will then […]

February 1, 2019 - 4 minutesmins - By Jonathan Smith

News and Trends 25 May 2018

Norwegian Pancreatic Cancer Vaccine Drastically Improves Survival

Targovax has obtained positive Phase I/II results showing its pancreatic cancer vaccine improved the survival of 32 patients also receiving chemotherapy over two years. Targovax, based in Oslo, Norway, has obtained positive Phase I/II results confirming the efficacy of its pancreatic cancer vaccine in a larger patient population and over a longer time period than […]

May 25, 2018 - 3 minutesmins - By Alexander Burik

News and Trends 8 Jan 2018

Bang and the Wart is Gone! Norwegian Peptide Destroys HPV-Infected Cells

Cytovation has raised over €3M to finish off pre-clinical testing of its treatment for warts, and to take it into the clinic. Norwegian biotech Cytovation is developing technology for the treatment of dermatological problems, including cutaneous warts caused by human papillomavirus. It lead candidate, CyPep-H1, uses a new mechanism of action to specifically target and destroy […]

January 8, 2018 - 3 minutesmins - By Alex Dale

News and Trends 20 Dec 2017

Christmas Has Come Early for Nordic Biotechs as a Norwegian Fund Readies €100M Injection

Hadean Ventures has closed its first fund, which it will begin to invest in life sciences companies around Europe, particularly in the Nordic region. Hadean Ventures is a VC fund based in Oslo, Norway, with the aim of improving healthcare to help patients that are suffering around the world. The VC has closed Hadean Capital […]

December 20, 2017 - 2 minutesmins - By Alex Dale

News and Trends 16 Nov 2017

Anti-Parasite Drug May Help to Treat Prostate Cancer, Say Norwegian Scientists

Researchers in Norway have found that a drug used to kill parasites like tapeworms can slow the growth of prostate and colon cancer cells. A group from the University of Bergen have been testing hundreds of drugs to see how they affect cancer cells. They have now found a drug taken to treat intestinal parasites, Giardia and […]

November 16, 2017 - 3 minutesmins - By Alex Dale

News and Trends 12 Sep 2017

Norwegian Biotech Announces Positive Phase I Results for T cell-Stimulating Vaccine

PCI Biotech’s T cell-stimulating vaccine enhances the cellular immune response, supporting it as a candidate for use alongside cancer vaccines. PCI Biotech, based in Oslo, Norway, has seen positive initial results in an ongoing Phase I trial for its firmaVacc technology. The trial is being carried out in 110 healthy subjects, and it aims to […]

September 12, 2017 - 2 minutesmins - By Alex Dale

Startup Scout 7 Jul 2017

A Norwegian Biotech is Aiming at Permanently Removing HPV Skin Infections

This week we’re traveling to Bergen, a beautiful coastal city in Norway surrounded by seven mountains, where a biotech called Cytovation is developing a brand new treatment for benign tumors caused by the human papillomavirus. Mission: Cytovation is developing what could be the first prescription treatment for cutaneous warts, which are a form of […]

July 7, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Interview 3 Jul 2017

These Norwegian Biotech Execs are Bringing Back Cancer Vaccines & Oncolytic Viruses

We talked to CEO Øystein Soug and CMO Magnus Jäderberg of Targovax about why the company’s technologies may succeed where others have failed. In 2010, Targovax rose from the ashes of Norsk Hydro Pharma, the discontinued therapeutic development arm of the conglomerate. The Oslo-based biotech is taking a stand against tough-to-treat cancers like that of […]

July 3, 2017 - 8 minutesmins - By Evelyn Warner

News and Trends 12 Jun 2017

Norwegian Biotech Hits €21M in Private Placement for its Immunotherapies

Targovax has raised €21M (NOK200M) in a private placement, which the biotech will use to fund data read-outs from clinical trials and CMC development. Targovax, based in Oslo, is developing a number of immunotherapies for treatment-resistant tumors. The biotech’s pipeline is based on its two platforms, ONCOS, an oncolytic virus, which is being developed to treat melanoma, […]

June 12, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 22 May 2017

Norwegian Biotech Goes for Combination Therapies in Melanoma

BerGenBio has started a new Phase I/II trial evaluating the addition of its Axl inhibitor to standard of care treatments in advanced melanoma. In March, Norwegian BerGenBio beat a biotech record on the Norwegian stock exchange, raising a massive €43.55M. Now, the company is standing by its promises and just dosed the first patient in a […]

May 22, 2017 - 2 minutesmins - By Melanie De Almeida

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us